In this episode of Executive Insights for Life Sciences Innovators, we speak with Jason Kralic, CEO and co-founder of Tellus Therapeutics, a biotechnology company focused on developing novel therapies for neonatal brain injury.

Jason discusses how Tellus is building a translational biotech platform grounded in strong biological insight and disciplined execution, with a clear focus on addressing one of the most complex and underserved patient populations in medicine.

He shares insights from his career journey as a neuropharmacologist and life sciences business development leader, including how his experience in large pharma and biotech informs the way he evaluates scientific risk, platform focus, and company strategy.

We explore the challenges of translating science into the clinic, the realities of capital strategy and timing in today’s funding environment, and Jason’s perspective on what it takes to build biotech companies designed to endure.

This episode was streamed live on YouTube on January 9, 2026. Learn more at ⁠⁠genecoda.com⁠⁠.

In this episode of Executive Insights for Life Sciences Innovators, we speak with Karthik Sriram, Vice President of Financial Planning & Analysis at Parabilis Medicines, a biopharmaceutical company developing next-generation peptide therapeutics through its innovative Helicon™ platform.

Karthik discusses how Parabilis is applying platform science and strategic financial planning to advance medicines designed to deliver extraordinary outcomes for patients. He shares insights from his career journey, transitioning from biomedical engineering into corporate strategy and biotech finance, and highlights how FP&A plays a central role in aligning scientific priorities with operational execution.

We explore the company’s vision for the Helicon™ platform, the opportunities and challenges of scaling a clinical-stage organization, and the broader trends shaping the future of peptide therapeutics and biotech company-building.

This episode was streamed live on YouTube on December 8, 2025.Learn more at ⁠genecoda.com⁠.

In this episode of Executive Insights for Life Sciences Innovators, we speak with Jim Buck, President & CEO of Medcura, a medical device company advancing surgical safety through innovative hemostatic and wound treatment solutions.

Jim discusses how Medcura is addressing one of healthcare’s most persistent challenges, rapid and reliable bleeding control, through a platform built on biocompatible, naturally derived polymers. He shares insights from his leadership journey, the company’s path from R&D to commercialization, and how Medcura’s technology is helping surgeons and patients achieve better outcomes in both surgical and wound care settings.

This episode was streamed live on YouTube on October 6, 2025.

Learn more at genecoda.com.

In this episode of Executive Insights for Life Sciences Innovators, we speak with Mike Stocum of Bantam Pharmaceutical, a biotech developing therapies that target cancer cells through their mitochondria. Mike shares how Bantam is advancing its lead programs and building a strategy to translate cutting-edge science into new treatment options for patients.

Learn more at ⁠genecoda.com⁠.

Originally recorded and streamed on YouTube Live on September 19, 2025.

In this episode of Executive Insights for Life Sciences Innovators, we speak with Mark Stead of Atomic AI, a biotech harnessing artificial intelligence and structural biology to unlock RNA’s therapeutic potential. Mark shares how Atomic AI is building a discovery platform to model RNA structures with unprecedented accuracy, opening the door to new classes of medicines for oncology, rare diseases, and beyond.

Learn more at genecoda.com.

Originally recorded and streamed on YouTube Live on August 22, 2025.

In this episode of Executive Insights for Life Sciences Innovators, we sit down with Larry Tiffany, CEO of GenrAb, to explore how the company is developing fully human neuroprotective antibodies to address neurodegenerative diseases such as ALS, Parkinson’s, and Alzheimer’s. Larry discusses GenrAb’s scientific approach, the promise of neuroprotection in slowing disease progression, and the challenges of advancing novel biologics in today’s biotech landscape.

Learn more at genecoda.com.

Originally recorded and streamed on YouTube Live on June 20, 2025.

In this episode of Executive Insights for Life Sciences Innovators, we sit down with Saurabh Johri, Chief Business Officer at Catena Biosciences, a pioneering company revolutionizing protein conjugation technologies for next-generation therapeutics. Saurabh shares insights on Catena’s platform, its potential to reshape therapeutic development, and the company’s vision for advancing precision medicine through novel protein engineering approaches.

Learn more at genecoda.com.

Originally recorded and streamed on YouTube Live on June 6, 2025.

In this episode of Executive Insights for Life Sciences Innovators, we sit down with Darren Dasburg, CEO of Clarus Biologics, a company advancing vaccine and immunology innovation through a novel adjuvant platform designed to improve immune responses, particularly in vulnerable populations. Darren shares insights on Clarus Biologics’ technology, its potential applications in global health, and the company’s strategy for bringing novel adjuvant solutions to market.

Learn more at genecoda.com.

Originally recorded and streamed on YouTube Live on May 19, 2025.

In this episode of Executive Insights for Life Sciences Innovators, we sit down with Ayla Annac, CEO and Co-Founder of InvivoSciences, a precision medicine company transforming the way therapies are discovered and developed for heart failure and cardiometabolic diseases. Ayla shares insights into InvivoSciences’ innovative platform, the promise of patient-specific models in drug discovery, and the company’s vision for advancing precision medicine.

Learn more at genecoda.com.

Originally recorded and streamed on YouTube Live on April 11, 2025.

In this episode of Executive Insights for Life Sciences Innovators, we speak with Anna Kazanchyan, MD, CEO of Saghmos Therapeutics, about the company’s mission to revolutionize cardiovascular and kidney protection. We explore how their lead drug candidate, ST-62516, is designed to prevent Major Adverse Cardiac and Kidney Events (MACKE) in high-risk patients undergoing PCI. Dr. Kazanchyan discusses the science behind ST-62516, why it has a strong likelihood of FDA approval, and the company’s strategic approach to clinical trials, regulatory success, and market exclusivity.

Learn more at genecoda.com.

Originally recorded and streamed on YouTube Live on March 28, 2025.